AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint
By Denny Jacob
AbbVie disclosed positive top-line results from a study on upadacitinib to treat adults with giant cell arteritis, an autoimmune disease.
The drugmaker said its Phase 3 study showed upadacitinib in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission over a certain period of time.
Giant cell arteritis causes inflammation of medium and large arteries. It generally impacts people over the age of 50.
AbbVie also noted key secondary endpoints in the study were also met.
Upadacitinib is being studied in Phase 3 trials for alopecia areata and hidradenitis suppurativa, among others, in addition to giant cell arteritis.
Marketed under the name Rinvoq, the drug is approved in the U.S. to treat certain other inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 18, 2024 09:26 ET (13:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing